Stocks and Investing Stocks and Investing
Wed, March 8, 2023
Tue, March 7, 2023

Sumant Kulkarni Maintained (CARA) at Strong Buy with Decreased Target to $25 on, Mar 7th, 2023


Published on 2024-10-28 02:09:42 - WOPRAI, Sumant Kulkarni
  Print publication without navigation


Sumant Kulkarni of Canaccord Genuity, Maintained "Cara Therapeutics, Inc." (CARA) at Strong Buy with Decreased Target from $29 to $25 on, Mar 7th, 2023.

Sumant, nor any peers, have made any analyst calls on CARA in the last 4 months.

Warning: Undefined array key "user_peer_history" in /tmp/a6c06072cf4de09d3b84c924bfa9ab126ebc2b66_0.file.analysis.tpl.php on line 30
Contributing Sources